Estimated percentage eligible ranges from 24 to 62 percent depending on eligibility criteria used
No increase observed in diagnoses following onset of COVID-19, but increase seen in proportion of women filling benzodiazepine prescription
Patients with CRS have increased risk for developing common psychiatric disorders and vice versa
Medication does not increase risk for depression, suicidal thoughts or behaviors among adults without known major psychopathology
Only high-dose psilocybin was better than placebo in antidepressant trials of escitalopram
Adding a ninth dimension based on depression scores by the Patient Health Questionnaires is feasible, authors say
Rates of depressive symptoms higher for cohort born from 1997 to 2001 compared with previous birth cohorts
Higher odds of past-month cannabis use linked to residing in states where cannabis is legal, past-year depressive episode
